Proving the possibility of treating Parkinson’s disease with Nexmos Aptamer

Nexmos announced on the 30th that it has published a research paper confirming the effect of improving Parkinson’s disease in animal experiments using aptamers in the international journal Neuroscience Letters. Aptamers are single-stranded nucleic acid substances capable of selectively binding to specific molecules. It has the advantage that there are more kinds of substances that can bind than antibodies and has a small molecular weight.

Nexmos put’NXP031′, a candidate for Parkinson’s disease treatment jointly developed with the research team of Professor Kim Yeon-jung of Kyung Hee University, into experimental mice administered with’MPTP’, a toxic substance causing Parkinson’s disease. As a result of administration of NXP031, the effect of suppressing cranial nerve inflammation was confirmed in the mice by improving movement disorders, neuroprotection, and suppressing microglia activation.

The company expects to be able to treat Parkinson’s disease by combining aptamers with antioxidants to increase the efficacy of antioxidants. Parkinson’s disease is a type of neurodegenerative disease caused by the loss of nerve cells that produce dopamine in the midbrain. Body tremors and stiffness, postural anxiety, and difficulty walking are the main symptoms. Along with dementia, it is a well-known degenerative brain disease, but the exact cause of the onset is not known until now. In some previous studies, it is assumed that one of the causes of Parkinson’s disease is the degeneration of dopamine-producing neurons due to harmful free radicals.

Kim Jeong-hoon, CEO of Nexmos, said, “This research paper is meaningful in that it overcomes the limitation that antioxidants cannot stay active in the body for a long time using the DNA aptamer platform technology and confirmed the effect of Parkinson’s disease treatment.” “We have proven that aptamer technology can be used as another solution to degenerative brain diseases such as dementia.”

Reporter Juhyun Lee [email protected]

Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution

Share on facebook
Facebook
Share on pinterest
Pinterest
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Proving the possibility of treating Parkinson’s disease with Nexmos Aptamer

Share on facebook
Facebook
Share on pinterest
Pinterest
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.